Mixed Pathologies and Cognitive Outcomes in Persons Considered for Anti-Amyloid Treatment Eligibility Assessment
Mixed pathologies are common among community-dwelling older persons considered for anti-amyloid treatment eligibility assessment. Beyond Aβ, tangles, LATE-NC, and vessel pathologies drive cognitive decline in this group of individuals, especially episodic memory decline. These findings suggest that, even among those eligible for anti-amyloid therapies, substantial cognitive decline may occur because of the presence of coexisting pathologies.
Authors
- David Alan Bennett (ORCID: https://orcid.org/0000-0003-3689-554X)
- Zoe Arvanitakis (ORCID: https://orcid.org/0000-0001-7477-8884)
- Julie A. Schneider (ORCID: https://orcid.org/0000-0002-9482-1752)
- Alifiya Kapasi (ORCID: https://orcid.org/0000-0003-1911-8482)
- Patricia A. Boyle (ORCID: https://orcid.org/0000-0002-3245-3456)
- Bryan D. James (ORCID: https://orcid.org/0000-0003-1932-151X)
- Ajay Sood (ORCID: https://orcid.org/0000-0002-9153-6198)
- Lei Yu (ORCID: https://orcid.org/0000-0002-0237-8758)
Institutions
- Rush University Medical Center (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1212/wnl.0000000000214004
- Citations
- 5
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.82